The estimated Net Worth of Daniel F Voytas is at least $480 mil dollars as of 18 December 2020. Daniel Voytas owns over 5,026 units of Calyxt Inc stock worth over $15,832 and over the last 7 years he sold CLXT stock worth over $181,187. In addition, he makes $282,667 as Chief Scientific Officer at Calyxt Inc.
Sign up
Daniel Voytas CLXT stock SEC Form 4 insiders trading
Daniel has made over 21 trades of the Calyxt Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 2,513 units of CLXT stock worth $10,379 on 4 January 2021.
The largest trade he's ever made was exercising 8,170 units of Calyxt Inc stock on 31 January 2019 worth over $30,311. On average, Daniel trades about 3,852 units every 41 days since 2018. As of 18 December 2020 he still owns at least 2,513 units of Calyxt Inc stock.
You can see the complete history of Daniel Voytas stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Daniel Voytas biography
Prof. Daniel F. Voytas, Ph.D., is Chief Science Officer of the company since May 2010. Dr. has served as our Chief Science Officer since May 2010. Dr. Voytas graduated summa cum laude from Harvard College in 1984 and received his Ph.D. in genetics from Harvard Medical School in 1990. He is one of our co-founders and one of the inventors of the TALEN technology. In addition to his role at Calyxt, Dr. Voytas is a professor in the Department of Genetics, Cell Biology and Development at the University of Minnesota (UMN), which he joined in 2008, and Director of the UMN’s Center for Genome Engineering and Director of the UMN’s Center for Precision Plant Genomics. In 1992, Dr. Voytas joined the faculty at Iowa State University. Prior to this, he conducted postdoctoral research at Johns Hopkins University School of Medicine. Dr. Voytas is an elected Fellow of the American Association for the Advancement of Science. In 2019, Dr. Voytas was elected to the National Academy of Sciences for his contributions to the field of gene editing and its applications to plant biology and agriculture.
What is the salary of Daniel Voytas?
As the Chief Scientific Officer of Calyxt Inc, the total compensation of Daniel Voytas at Calyxt Inc is $282,667. There are 6 executives at Calyxt Inc getting paid more, with James Blome having the highest compensation of $4,488,350.
How old is Daniel Voytas?
Daniel Voytas is 57, he's been the Chief Scientific Officer of Calyxt Inc since 2010. There are 4 older and 9 younger executives at Calyxt Inc. The oldest executive at Calyxt Inc is Philippe Dumont, 68, who is the Independent Director.
What's Daniel Voytas's mailing address?
Daniel's mailing address filed with the SEC is Mount Ridge Road, Roseville, Ramsey County, Minnesota, 55113-5499, United States.
Insiders trading at Calyxt Inc
Over the last 7 years, insiders at Calyxt Inc have traded over $2,578,214 worth of Calyxt Inc stock and bought 116,475 units worth $1,447,167 . The most active insiders traders include Kimberly K. Nelson, Daniel F Voytas y Yves J Ribeill. On average, Calyxt Inc executives and independent directors trade stock every 23 days with the average trade being worth of $35,853. The most recent stock trade was executed by Yves J Ribeill on 19 September 2022, trading 30,000 units of CLXT stock currently worth $7,200.
What does Calyxt Inc's logo look like?
Complete history of Daniel Voytas stock trades at Calyxt Inc
Calyxt Inc executives and stock owners
Calyxt Inc executives and other stock owners filed with the SEC include:
-
James Blome,
Chief Executive Officer, Director -
William Koschak,
Chief Financial Officer -
Debra Frimerman,
General Counsel -
Kimberly Nelson,
Independent Director -
William F. Koschak,
Chief Financial Officer -
Dr. Travis J. Frey Ph.D.,
Chief Technology Officer -
Daniel Voytas,
Chief Scientific Officer -
Philippe Dumont,
Independent Director -
Yves Ribeill,
Chairman of the Board -
Christopher Neugent,
Independent Director -
Anna Kozicz-Stankiewicz,
Independent Director -
Jonathan Fassberg,
Independent Director -
Chris Tyson,
IR Contact Officer -
Laurent Arthaud,
Director -
Bobby Williams,
Director - Gene Editing -
Vince Restucci,
Vice President of Agronomy Services -
Sarah Reiter,
Vice President - Business Development -
Travis Frey,
Chief Technology Officer -
Keith Blanks,
Senior Vice President of Sales and Marketing -
Gerry Nuovo,
Sr. VP of Bus. Devel. -
Dr. Stephen M. Bravo,
Chief Medical Officer -
Trina Lundblad,
Director of Communications -
Debra H. Frimerman,
Gen. Counsel & Corp. Sec. -
Dr. Daniel F. Voytas Ph.D.,
Founder, Chief Science Officer & Chair of Scientific Advisory Board -
Michael Allen Carr,
Pres, CEO & Director -
Michael A. Carr,
President and CEO -
Manoj Sahoo,
Chief Commercial Officer -
Alain Godard,
Director -
Bryan W.J. Corkal,
Chief Financial Officer -
Michel Arbadji,
Director of Business Developme -
Federico A. Tripodi,
Chief Executive Officer -
Glenn R Bowers,
Vice President of Breeding -
S.A. Cellectis,
10% owner